-
Overview
Date & Location
12/15/2020 – 12/15/2021, 12:00 AM CST Online
Overview
This episode describes monoclonal antibodies bamlanivimab and casirivimab/imdevimab and the FDA Emergency Use Authorization for these agents. Criteria for use, including patients who are eligible and not eligible for this therapy are discussed, and potential benefits of therapy. The Regional Infusion Center, a unique collaboration between the Regional Advisory Council, San Antonio Fire and EMS, and local hospitals, is described and discussed.
Target Audience
This educational activity is designed to meet the educational goals of physicians and other healthcare professionals specializing in infectious diseases, family and community medicine, internal medicine, emergency medicine, and all those involved with the management of patients with coronavirus.
Learning Objectives for the Episode 5
- Describe the monoclonal antibodies and their potential benefit.
- List those who are eligible to recieve monoclonal antibodies for potential benefit.
- List those who are not eligible to recieve monoclonal antibodies.
- Describe the Regional Infusion Center that is a result of collaboration in San Antonio area.
Program Registration Information
Registration Fees - $0.00
Continuing Medical Education Education Credit - Accreditation and Designation Statement
The Joe R. and Teresa Lozano Long School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Long School of Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Certificate of Attendance
Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance.
Credit may be obtained upon successful completion of the activity’s evaluation.
Release date: 12/15/2020 Credits expire: 12/15/2021
-
Faculty
Jan E. Patterson, MD, MS, MACP
FIDSA, FSHEA, CHCP
Professor of Medicine/Infectious Diseases and Pathology
Associate Dean for Quality & Lifelong Learning
Joe R. and Teresa Lozano Long School of Medicine
º£½ÇÂ×ÂÒDr. Patterson is a Professor of Medicine/Infectious Diseases and Associate Dean for Quality & Lifelong Learning at The Joe R. and Teresa Lozano Long School of Medicine, º£½ÇÂ×ÂÒ. She is clinician and a healthcare epidemiologist and has served on the Infectious Diseases Society of America Board of Directors and is Past President of the Society for Healthcare Epidemiology of America. She is a longtime infectious diseases consultant to Southwest Texas Regional Advisory Council (STRAC) and has also served on CDC’s Healthcare Infection Practices Advisory Committee and has been a consultant to San Antonio Metro Health Department. She has been a site principal investigator for new antimicrobial agents and is currently a co-investigator for the NIH Adaptive COVID-19 Treatment Trial (ACTT) studies as outlined above and is a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health and University Hospital.
C. J. Winckler, MD
Assistant Professor/Clinical
Deputy Medical Director, San Antonio Fire Department
Joe R. and Teresa Lozano Long School of Medicine
º£½ÇÂ×ÂÒDr. C. J. Winckler is an Assistant Professor of Emergency Health Services at º£½ÇÂ×ÂÒ and Deputy Medical Director for the San Antonio Fire Department / Emergency Medical Services.
Relevant Financial Disclosures
Dr. Jan Patterson has disclosed that she is a NIH ACTT co-investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial.
Dr. C.J. Winckler does not have any relevant financial relationships to disclose.
